Bernstein Paul S, Horn Rachael Sue
Moran Eye Center, University of Utah, Salt Lake City, USA.
Retina. 2008 Jan;28(1):81-4. doi: 10.1097/IAE.0b013e31815e9351.
To report the outcome of consecutive patients treated with verteporfin photodynamic therapy in which the treatment zone overlapped the optic nerve.
Retrospective interventional case series with chart review of seven patients with peripapillary choroidal neovascularization secondary to age-related macular degeneration treated with standard-dose verteporfin photodynamic therapy.
The first of seven patients had excellent visual outcome with visual acuity measurement improved from 20/80 to 20/20 at 6 months post-treatment which remained stable for over 2 years. All remaining patients had improvement of visual acuity with resolution of peripapillary hemorrhage. Only two of the seven patients required more than one treatment with verteporfin photodynamic therapy.
Peripapillary choroidal neovascular membranes can be successfully treated with standard-dose verteporfin photodynamic therapy, often with resolution of neovascularization with one treatment. There was no evidence of optic nerve damage from the intervention.
报告连续接受维替泊芬光动力疗法治疗且治疗区域与视神经重叠的患者的治疗结果。
回顾性介入病例系列研究,对7例年龄相关性黄斑变性继发视乳头周围脉络膜新生血管的患者进行病历审查,采用标准剂量维替泊芬光动力疗法治疗。
7例患者中的首例在治疗后6个月视力测量从20/80提高到20/20,视觉效果极佳,且在2年多的时间里保持稳定。其余所有患者视力均有改善,视乳头周围出血消退。7例患者中只有2例需要接受不止一次维替泊芬光动力疗法治疗。
视乳头周围脉络膜新生血管膜可以通过标准剂量维替泊芬光动力疗法成功治疗,通常一次治疗即可使新生血管消退。没有证据表明该干预会对视神经造成损害。